» Articles » PMID: 9265910

Efficacy of Olanzapine: an Overview of Pivotal Clinical Trials

Overview
Specialty Psychiatry
Date 1997 Jan 1
PMID 9265910
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Olanzapine is a new "atypical" antipsychotic agent that belongs chemically to the thienobenzodiazepine class. Its relatively greater binding affinity for 5-HT2 compared to D2 receptors makes it similar to the atypical agent clozapine, a serotonin/dopamine antagonist. Four double-blind pivotal studies, which compare olanzapine to placebo and/or haloperidol, are presented. The results suggest that olanzapine is as effective as haloperidol for positive symptoms and more effective than haloperidol for the treatment of the negative symptoms of schizophrenia.

Citing Articles

Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study.

Correll C, Koblan K, Hopkins S, Li Y, Dworak H, Goldman R NPJ Schizophr. 2021; 7(1):63.

PMID: 34887427 PMC: 8660889. DOI: 10.1038/s41537-021-00190-z.


Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines.

Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S Support Care Cancer. 2015; 23(9):2649-54.

PMID: 25680763 DOI: 10.1007/s00520-015-2625-9.


Haloperidol versus placebo for schizophrenia.

Adams C, Bergman H, Irving C, Lawrie S Cochrane Database Syst Rev. 2013; (11):CD003082.

PMID: 24242360 PMC: 11558230. DOI: 10.1002/14651858.CD003082.pub3.


A case of neuroleptic malignant syndrome induced by olanzapine in postpartum period.

Ustundag M, Orak M, Guloglu C, Burak Sayhan M, Tas M Indian J Psychiatry. 2010; 49(4):287-9.

PMID: 20680143 PMC: 2910354. DOI: 10.4103/0019-5545.37671.


Neuroprotective effect of atypical antipsychotics in cognitive and non-cognitive behavioral impairment in animal models.

He J, Kong J, Tan Q, Li X Cell Adh Migr. 2009; 3(1):129-37.

PMID: 19372744 PMC: 2675159. DOI: 10.4161/cam.3.1.7401.